Publikationsdatenbank

A model for epilepsy of infectious etiology using Theiler's murine encephalomyelitis virus (2022)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Batot, Gaelle

Metcalf, Cameron S.

Bell, Laura A.

Pauletti, Alberto (WE 14)

Wilcox, Karen S.

Bröer, Sonja (WE 14)

Quelle

Journal of visualized experiments : JoVE

Heftzählung: 184

Seiten: Artikel e63673

ISSN: 1940-087x

Sprache

Englisch

Verweise

URL (Volltext): https://www.jove.com/t/63673/a-model-for-epilepsy-infectious-etiology-using-theiler-s-murine

DOI: 10.3791/63673

Kontakt

Institut für Pharmakologie und Toxikologie

Koserstr. 20
14195 Berlin
+49 30 838 53221
pharmakologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

One of the main causes of epilepsy is an infection of the central nervous system (CNS); approximately 8% of patients who survive such an infection develop epilepsy as a consequence, with rates being significantly higher in less economically developed countries. This work provides an overview of modeling epilepsy of infectious etiology and using it as a platform for novel antiseizure compound testing. A protocol of epilepsy induction by non-stereotactic intracerebral injection of Theiler's murine encephalomyelitis virus (TMEV) in C57BL/6 mice is presented, which replicates many of the early and chronic clinical symptoms of viral encephalitis and subsequent epilepsy in human patients. The clinical evaluation of mice during encephalitis to monitor seizure activity and detect the potential antiseizure effects of novel compounds is described. Furthermore, histopathological consequences of viral encephalitis and seizures such as hippocampal damage and neuroinflammation are shown, as well as long-term consequences such as spontaneous epileptic seizures. The TMEV model is one of the first translational, infection-driven, experimental platforms to allow for the investigation of the mechanisms of epilepsy development as a consequence of CNS infection. Thus, it also serves to identify potential therapeutic targets and compounds for patients at risk of developing epilepsy following a CNS infection.